摘要
特应性皮炎是一种常见的慢性炎症性皮肤病,严重影响患者的生活质量。近几年,多种新型生物制剂和小分子口服药物已被批准用于治疗特应性皮炎。Janus激酶抑制剂通过抑制多种Th2细胞介导的炎症、表皮屏障功能受损、瘙痒信号传导等途径,对特应性皮炎起到治疗作用。本文报道了两例难治性特应性皮炎儿童患者成功使用JAK抑制剂治疗的案例。
Atopic dermatitis(AD)is a common chronic inflammatory skin disease that significantly impairs the quality of life.Recently,novel biologics and small-molecule oral drugs have gained approval for the treatment of AD.Janus kinase(JAK)inhibitors play a therapeutic role in atopic dermatitis by inhibiting various Th2 cell-mediated inflammation,impaired epidermal barrier function,and pruritus signaling pathways.This article reports two cases of pediatric patients with refractory atopic dermatitis successfully treated with JAK inhibitors.
作者
韩京宏
刘红
HAN Jinghong;LIU Hong(Hospital for Skin Diseases,Shandong First Medical University,Jinan 250022,China;Shandong Provincial Institute of Dermatology and Venereology,Shandong Academy of Medical Sciences,Jinan 250022,China)
出处
《中国麻风皮肤病杂志》
2024年第3期190-192,共3页
China Journal of Leprosy and Skin Diseases
基金
山东省皮肤性病学临床医学研究中心。
